[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Comparative Effectiveness of an Individualized Model of Hemodialysis Versus Conventional Hemodialysis


Description

This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function. The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.This study will analyze the effects of differentiated care with individualized hemodialysis on patient health related quality of life, fatigue, employment, and caregiver burden in patients with Kidney dysfunction requiring dialysis (KDRD) and appreciable kidney function. This study will compare the outcomes in survival, hospitalization, preservation of the kidney function and quality of life between hemodialysis tailored to each patient needs

Trial Eligibility

Patient eligibility Criteria: Inclusion Criteria: * Clinical Inclusion Criteria: * Age ≥ 18 years * Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 12 weeks * Has received ≤36 sessions of intermittent HD (i.e., on HD for ≤12 weeks) at the time patient is approached for potential study participation Residual Kidney Function Inclusion Criteria: * Kidney urea clearance \<2.0 mL/min * Urine volume# of ≥500 mL/24 h Exclusion Criteria: * Pre-HD serum K ≥5.8 mEq/L, Na ≤125 mEq/L, or bicarbonate level ≤17 mEq/L * Requirement or anticipated requirement of high-volume ultrafiltration * Unable or unwilling to follow the study protocol for any reason * Known pregnancy or planning to attempt to become pregnant or lactating women * Estimated survival or dialysis modality change or center transfer \<6 months Caregiver Eligibility Criteria: * be at least 18 years old * be the main caregiver (at patient's choice) * be a close relative of the patient (spouse, child, sibling, parent, grandchild) * have no known psychiatric and neurologic disorders (through direct inquiry from the person) * not be a member of the medical or healthcare team * not be the caregiver for another patient with chronic illness * not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)

Study Info

Organization

Wake Forest University Health Sciences


Primary Outcome

Number of Clinical events of safety


Outcome Timeframe year 2

NCTID NCT05828823

Phases NA

Primary Purpose TREATMENT

Start Date 2024-02-26

Completion Date 2027-09

Enrollment Target 350

Interventions

DEVICE Hemodialysis twice weekly

OTHER Hemodialysis thrice weekly

Locations Recruiting

University of Florida

United States, Florida, Jacksonville


Emory University

United States, Georgia, Atlanta


Johns Hopkins University School of Medicine (JHUSM)

United States, Maryland, Baltimore


Renal Research Institute (RRI)

United States, New York, New York


University of North Carolina Chapel Hill

United States, North Carolina, Chapel Hill


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.